絞り込み

16555

広告

J-Startupをはじめとするベンチャー企業の入札機会を拡大します

経済産業省は、関係府省庁と連携して、政府調達に関する統一基準を改訂しました。これにより、あらゆる規模の政府調達に対してJ-Startup企業の入札が可能となりま...

  1. FB、副社長に英の元副首相 規制強化のE...
  2. 選手は1型糖尿病 日本の患者励まし参戦 ...
  3. 日欧の水星探査機、打ち上げ成功…25年に...
  4. いつになったら我々は地球工学しか方法はな...

ニュース一覧

Correlation of Bone Mineral Density on Quality of Life in Patients with Osteogenesis Imperfecta during Treatment with Denosumab.

著者 Hoyer-Kuhn H , Stark C , Franklin J , Schoenau E , Semler O
Pediatr Endocrinol Rev.2017 Nov ; 15(Suppl 1):123-129.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (52view , 0users)
Osteogenesis imperfecta (OI) is a rare hereditary skeletal disease leading to recurrent fractures, short stature and impaired mobility. The phenotype varies from mildly affected patients to perinatal lethal forms. In most cases an impaired collagen production due to mutations in COL1A1 or COL1A2 cause this hereditary bone fragility syndrome with an autosomal dominant inheritance. Currently an interdisciplinary therapeutic approach with antiresorptive drugs, physiotherapy and surgical procedures is the state of the art therapy. The effect of such a therapy is evaluated by measuring different surrogate parameters like areal bone mineral density or by using different mobility tests or questionnaires. Up till now the impact of these parameters on quality of life of the patients is not evaluated. Currently pharmacological strategies are based on antiresorptive treatment with bisphosphonates. In this trial we investigated the effect of an antiresorptive therapy with the monoclonal antibody denosumab decreasing the activity of osteoclasts. Denosumab was administered subcutaneously in a dose of 1mg/kg body weight in 10 children with OI (5-10 years of age) every 12 weeks for 48 weeks. Areal bone mineral density, mobility, pain scores and quality of life were measured. The results showed a good effect of the treatment on bone mineral density but this improvement showed no correlation to pain and quality of life. In conclusion further trials have to define parameters to assess interventions which influence activities of daily life of the patients. An interdisciplinary approach including physicians, basic researchers and patient organisation is needed to focus research on topics improving quality of life of patients with severe skeletal diseases.
PMID: 29292876 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード